retatrutide trials Eli Lilly infiltrates anti-obesity market as Phase III trial for begins Retatrutide, an investigational triple hormone

Levels above 90 mg/dL increase the risk for heart disease, regardless of what your total cholesterol number is

Report serious adverse events to the FDA's MedWatch program

Bariatric Surgery and Post-Procedural Coding Z98.84 (bariatric surgery status) is reported as a secondary code at any subsequent encounter when the history is clinically relevant

It is directionally helpful

GLP-1 medications do not selectively target abdominal fat but promote generalised weight loss through appetite suppression and reduced caloric intake

effective contraception is recommended for women of childbearing potential Individuals with renal impairment : whilst no routine dose adjustment is required for the class, there is an increased risk of dehydration and acute kidney injury from gastrointestinal side effects, and monitoring is advised Individuals with hepatic impairment : limited data are available